These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36246617)

  • 1. Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer.
    Hu M; Yao W; Shen Q
    Front Genet; 2022; 13():1005658. PubMed ID: 36246617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
    Yin X; Wu T; Lan Y; Yang W
    Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.
    Liu Z; Liu X; Liang J; Liu Y; Hou X; Zhang M; Li Y; Jiang X
    Front Immunol; 2021; 12():765101. PubMed ID: 34675942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect.
    Huang Y; Zhang Y; Zhang M; Zhao K; Feng L; Guan J; Dong R; Liu J; Tian D; Liu M; Xia S; Liao J
    Crit Rev Oncol Hematol; 2023 Sep; 189():104070. PubMed ID: 37468083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in immunotherapy for hepatocellular carcinoma.
    Khan AA; Liu ZK; Xu X
    Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma Immunotherapy.
    Sperandio RC; Pestana RC; Miyamura BV; Kaseb AO
    Annu Rev Med; 2022 Jan; 73():267-278. PubMed ID: 34606324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.
    Liu X; Lei X; Huang S; Yang X
    Comb Chem High Throughput Screen; 2023 Nov; ():. PubMed ID: 38031784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Traditional Chinese medicine in the era of immune checkpoint inhibitor: theory, development, and future directions.
    Yu YX; Wang S; Liu ZN; Zhang X; Hu ZX; Dong HJ; Lu XY; Zheng JB; Cui HJ
    Chin Med; 2023 May; 18(1):59. PubMed ID: 37210537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress of immunotherapy alone and in combination for liver cancer].
    Wu ZJL; Li K; Zhang K; Gong WD
    Zhonghua Gan Zang Bing Za Zhi; 2020 Jun; 28(6):471-474. PubMed ID: 32660173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
    Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
    World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
    Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
    Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
    Feng GS; Hanley KL; Liang Y; Lin X
    Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):104-114. PubMed ID: 32715491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
    He Y; Lu M; Che J; Chu Q; Zhang P; Chen Y
    Front Oncol; 2021; 11():716844. PubMed ID: 34552872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint and angiogenic inhibitors for the treatment of hepatocellular carcinoma: It takes two to tangle.
    Sukowati C; Cabral LKD; Tiribelli C
    Ann Hepatol; 2022; 27(5):100740. PubMed ID: 35809835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.